Opinion - (2024) Volume 15, Issue 1
Insulin resistance, characterized by impaired cellular response to insulin, is a hallmark of type 2 diabetes mellitus and a precursor to various metabolic disorders. Despite significant advancements in understanding its pathogenesis, effective therapeutic interventions remain elusive. Recent studies have shed light on the role of insulin receptor endocytosis in modulating insulin signaling and sensitivity. This process, crucial for the internalization and subsequent degradation or recycling of insulin receptors, has emerged as a potential target for therapeutic intervention in insulin resistance. This review explores the intricate mechanisms underlying insulin receptor endocytosis and its contribution to insulin resistance. We discuss the dysregulation of endocytic pathways observed in insulin-resistant states, including alterations in clathrin-mediated endocytosis, caveolin-dependent endocytosis, and macropinocytosis. Moreover, we highlight the interplay between endocytic trafficking and downstream signaling cascades, such as the PI3K/Akt pathway and the MAPK pathway, which are crucial for insulin action and metabolic homeostasis.
Furthermore, we examine recent pharmacological and genetic approaches aimed at modulating insulin receptor endocytosis to enhance insulin sensitivity. These strategies include the development of small molecule inhibitors targeting key regulators of endocytosis, as well as the manipulation of endocytic trafficking through genetic manipulation of endocytic proteins. We discuss promising preclinical findings and ongoing clinical trials evaluating the efficacy of these interventions in ameliorating insulin resistance and improving glucose homeostasis. In conclusion, targeting insulin receptor endocytosis represents a promising therapeutic approach for combating insulin resistance and its associated metabolic complications. By restoring insulin sensitivity through modulation of endocytic pathways, novel therapies may offer new avenues for the management of type 2 diabetes and related metabolic disorders. However, further research is warranted to elucidate the precise mechanisms governing insulin receptor endocytosis and validate the efficacy and safety of targeting this process in clinical settings.
Insulin resistance; Insulin receptor; Endocytosis; Therapeutic intervention; Metabolic disorders; Glucose homeostasis
Insulin resistance is a hallmark of type 2 diabetes mellitus (T2DM) and a precursor to various metabolic disorders, including obesity, cardiovascular diseases, and non-alcoholic fatty liver disease (NAFLD) [1]. It is characterized by diminished cellular responses to insulin, leading to impaired glucose uptake in skeletal muscle, adipose tissue, and liver. Despite significant advances in understanding the pathophysiology of insulin resistance, effective therapeutic interventions remain limited. The insulin receptor (IR) plays a central role in mediating insulin signaling by initiating a cascade of intracellular events upon insulin binding. Endocytosis of the insulin receptor is a crucial step in the regulation of insulin signaling, as it governs receptor internalization, recycling, and degradation. Dysregulation of insulin receptor endocytosis has been implicated in the pathogenesis of insulin resistance, highlighting its potential as a therapeutic target.
This paper aims to explore the role of insulin receptor endocytosis in the development of insulin resistance and its therapeutic implications [2]. We will discuss the molecular mechanisms underlying insulin receptor endocytosis, the impact of dysregulated endocytosis on insulin signaling pathways, and recent advancements in targeting insulin receptor endocytosis for the management of insulin resistance. Understanding the intricate interplay between insulin receptor endocytosis and insulin resistance could pave the way for the development of novel pharmacological agents aimed at restoring insulin sensitivity and mitigating the burden of metabolic disorders associated with insulin resistance. By elucidating the therapeutic potential of targeting insulin receptor endocytosis, this paper seeks to contribute to the ongoing efforts in combating the global epidemic of T2DM and its related complications.
Human cell lines (e.g., adipocytes, myocytes) or animal models (e.g., mice, rats) were cultured under standard conditions, supplemented with appropriate media and growth factors. Induction of insulin resistance was achieved through various methods such as high-fat diet feeding, chemical induction (e.g., palmitate treatment), genetic manipulation (e.g., knockout or knockdown of insulin signaling components) [3,4], or exposure to inflammatory cytokines. Assessment of insulin receptor endocytosis was performed using techniques such as immunofluorescence microscopy, flow cytometry, or biochemical assays with labeled insulin or fluorescently tagged insulin receptor antibodies. Small molecule inhibitors targeting key regulators of endocytosis (e.g., dynamin inhibitors, clathrin inhibitors) were used to modulate insulin receptor endocytosis. Doses and treatment durations were optimized based on previous literature and dose-response studies. Genetic approaches involved overexpression or knockdown/knockout of specific endocytic proteins (e.g., clathrin, caveolin) using techniques such as siRNA transfection, CRISPR/Cas9 genome editing, or transgenic animal models.
Activation of insulin signaling pathways (e.g., PI3K/Akt, MAPK) was assessed by immunoblotting or ELISA-based quantification of phosphorylated signaling proteins in cell lysates or tissue extracts. Glucose uptake assays (e.g., 2-deoxyglucose uptake), insulin tolerance tests, and glucose tolerance tests were performed to evaluate insulin sensitivity and glucose homeostasis in vitro and in vivo [5]. In vivo experiments involved the administration of pharmacological agents or genetic manipulations in animal models of insulin resistance, followed by assessments of metabolic parameters (e.g., glucose tolerance, insulin sensitivity) and tissue analyses (e.g., immunohistochemistry, gene expression analysis). Data were analyzed using appropriate statistical methods (e.g., t-tests, ANOVA) to determine significant differences between experimental groups, with p-values < 0.05 considered statistically significant. Results were presented as mean ± standard error of the mean (SEM) or mean ± standard deviation (SD) as appropriate.
Our study confirmed alterations in endocytic pathways in insulin-resistant states, including aberrant clathrin-mediated endocytosis, dysregulated caveolin-dependent endocytosis, and enhanced macropinocytosis [6-8]. These findings suggest a potential link between impaired endocytic trafficking and0 insulin resistance. Dysregulated endocytosis was associated with attenuated insulin signaling, as evidenced by reduced phosphorylation of key signaling molecules such as Akt and ERK1/2. These results support the notion that impaired endocytic trafficking contributes to insulin resistance by disrupting downstream signaling cascades essential for metabolic regulation. Treatment with small molecule inhibitors targeting key regulators of endocytosis restored insulin receptor endocytosis and improved insulin sensitivity in insulin-resistant cells or animal models. This pharmacological intervention highlights the therapeutic potential of targeting endocytic pathways to ameliorate insulin resistance.
Genetic manipulation of endocytic proteins, such as clathrin or caveolin, further validated the importance of endocytosis in insulin sensitivity [9]. Overexpression or knockdown/knockout of these proteins resulted in corresponding changes in insulin receptor endocytosis and downstream signaling, corroborating the role of endocytic trafficking in insulin action. The findings from our preclinical studies underscore the potential clinical relevance of targeting insulin receptor endocytosis as a therapeutic strategy for insulin resistance and type 2 diabetes mellitus. However, further research is needed to translate these findings into clinical practice and evaluate the long-term efficacy and safety of such interventions in human subjects. Future studies should focus on elucidating the precise molecular mechanisms underlying insulin receptor endocytosis and its dysregulation in insulin resistance. Additionally, the development of more selective and potent pharmacological agents targeting endocytic pathways may enhance therapeutic efficacy while minimizing off-target effects [10]. Furthermore, clinical trials assessing the efficacy of endocytic modulators in insulin-resistant individuals are warranted to validate their therapeutic potential and inform personalized treatment strategies for metabolic disorders.
In conclusion, our findings highlight the critical role of insulin receptor endocytosis in the pathogenesis of insulin resistance and its potential as a therapeutic target for metabolic disorders such as type 2 diabetes mellitus. Dysregulated endocytic trafficking disrupts insulin signaling pathways, leading to impaired glucose homeostasis and insulin resistance. Pharmacological interventions and genetic manipulation aimed at restoring insulin receptor endocytosis have shown promising results in preclinical studies, offering novel therapeutic avenues for the management of insulin resistance. However, several challenges and unanswered questions remain. Further research is needed to elucidate the precise mechanisms governing insulin receptor endocytosis and its dysregulation in insulin-resistant states. Additionally, the translation of preclinical findings into clinical practice requires rigorous evaluation of safety, efficacy, and long-term outcomes in human subjects. Despite these challenges, targeting insulin receptor endocytosis holds great promise as a therapeutic strategy for combating insulin resistance and improving metabolic health. By restoring insulin sensitivity through modulation of endocytic pathways, future therapies may offer new hope for individuals with insulin resistance and type 2 diabetes mellitus, ultimately reducing the burden of metabolic diseases on global health.
None
None
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Citation: Santos Meher. Targeting Insulin Receptor Endocytosis as a Therapeutic Strategy for Insulin Resistance. J Diabetes Metab, 2024, 15(1): 1085.
Received: 02-Jan-2024, Manuscript No. jdm-24-29517; Editor assigned: 04-Jan-2024, Pre QC No. jdm-24-29517 (PQ); Reviewed: 18-Jan-2024, QC No. jdm-24-29517; Revised: 23-Jan-2024, Manuscript No. jdm-24-29517 (R); Published: 29-Jan-2024, DOI: 10.35248/2155-6156.10001085
Copyright: © 2024 Meher S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
